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ORIGINAL INVESTIGATION
Effect of sitagliptin on tissue 
characteristics of the carotid wall in patients 
with type 2 diabetes: a post hoc sub-analysis 
of the sitagliptin preventive study 
of intima-media thickness evaluation (SPIKE)
Naoto Katakami1,2* , Tomoya Mita3,4, Yoko Irie5, Mitsuyoshi Takahara1,6, Taka‑aki Matsuoka1, Masahiko Gosho7, 
Hirotaka Watada3,4,8, Iichiro Shimomura1 and on behalf of the Sitagliptin Preventive study of Intima‑media 
thickness Evaluation (SPIKE) Collaborators
Abstract 
Background: Ultrasonic gray‑scale median (GSM) of the carotid wall reflects its composition and low‑GSM carotid 
plaque is considered to be vulnerable. This study aimed to evaluate the effect of sitagliptin, a dipeptidyl peptidase‑4 
inhibitor, on the longitudinal change in GSM, an index of the tissue characteristics of the carotid wall, in patients with 
type 2 diabetes mellitus (T2DM).
Methods: This is a post hoc sub‑analysis using data obtained from the SPIKE trial, a randomized controlled trial that 
demonstrated the beneficial effect of sitagliptin on the progression of carotid intima‑media thickness in patients with 
T2DM. A total of 274 T2DM patients with no past history of apparent cardiovascular disease (137 in the sitagliptin 
treatment group and 137 in the conventional treatment group) were enrolled. The primary outcome was the change 
from baseline in mean GSM‑CCA during the 104‑week treatment period.
Results: The mean GSM‑CCA significantly increased in the sitagliptin treatment group (adjusted ΔGSM = 2.40 ± 1.19 
[mean ± SE], p = 0.044) but not in the conventional treatment group (adjusted ΔGSM = 1.32 ± 1.19, p = 0.27). How‑
ever, there was no significant difference in changes in mean GSM‑CCA between the treatment groups.
Conclusions: A post hoc sub‑analysis suggests that the tissue characteristics of the carotid arterial wall were 
improved in the sitagliptin treatment group during the 104‑week treatment period, but not in the conventional 
treatment group. However, there was no between‑group difference in the changes of GSM values between the two 
treatment groups. Prespecified studies with large sample sizes would be necessary to confirm our findings.
Trial registration UMIN000028664, Registered 15 August 2017 (“retrospectively registered”)
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Introduction
Disruption of unstable atherosclerotic plaque plays a 
crucial role in the pathogenesis of cardiovascular disease 
(CVD) events. Plaque disruption is dependent on the tis-
sue characteristics of the plaque lesion: the lipid content, 
the presence of neovascular vessels, inflammatory cells in 
the atheroma, and the thickness of the fibrous cap [1–4]. 
Since diabetes mellitus (DM) is related to increased vul-
nerability to plaque disruption and higher incidence of 
clinical CVD [5], stabilization of unstable plaque would 
be critical to reducing the incidence of CVD events in the 
management of DM.
Dipeptidyl peptidase-4 (DPP-4) inhibitors, which 
inhibit the degradation of active incretins includ-
ing glucagon-like polypeptide-1 (GLP-1) by DPP-4, 
increase the concentration of active incretins and thereby 
improved glycemic control with low hypoglycemia risk. 
Furthermore, these agents potentially have anti-ath-
erosclerotic properties beyond their glucoregulatory 
effects [6, 7]. Several experimental studies have shown 
that DPP-4 inhibitors can inhibit foam cell formation 
and atherosclerosis in both GLP-1-dependent and GLP-
1-independent manners [8–13]. Such anti-inflammatory 
and anti-atherosclerotic effects of DPP-4 inhibitors have 
also been confirmed by studies conducted in clinical set-
tings [14, 15]. Furthermore, several studies demonstrated 
that DPP-4 inhibitors prevented increase in carotid 
intima-media thickness (IMT), an established marker of 
early-stage atherosclerosis [16–19], in patients with type 
2 diabetes (T2DM) compared with conventional treat-
ment [20–22]. However, little is known about the effect of 
DPP-4 inhibitors on the tissue characteristics of athero-
sclerotic lesions in the carotid wall.
Interestingly, a recent study indicates that noninvasive 
ultrasonic tissue characterization of carotid plaque using 
gray-scale median (GSM) reflects plaque composition. 
Low-GSM plaque, which is characterized by high lipid 
content, neovascular vessels, and inflammatory infiltration, 
is considered to be particularly unstable [23]. Furthermore, 
the GSM value in the carotid wall can serve as a predic-
tor of future CVD events [24–26]. The presence of echo-
lucent low GSM plaque as well as plaque thickness were 
independent predictors of CVD, even after adjustment for 
other risk factors, and the addition of plaque echogenicity 
(presence/absence of echolucent plaque) and plaque thick-
ness to the conventional risk factors and plaque thickness 
resulted in further and significant improvement of the risk 
prediction of CVD in asymptomatic patients with T2DM 
[25]. Thus, IMT and GSM reflect different aspects of ath-
erosclerotic changes in the prediction of and the risk of 
cardiovascular disease. Therefore, it would be worthwhile 
to evaluate the effect of anti-diabetic agents on the longitu-
dinal change in the GSM value.
The aim of the present study is to evaluate the effect of 
sitagliptin, a DPP-4 inhibitor, on the longitudinal change 
in the GSM value, an index of the ultrasonic tissue char-
acteristics of the carotid wall, in patients with T2DM, 
using data obtained from the Sitagliptin Preventive study 
of Intima-media thickness Evaluation (SPIKE) trial [22].
Research design and methods
The present study was a post hoc analysis based on 
data obtained from the Sitagliptin Preventive study of 
Intima-media thickness Evaluation (SPIKE) trial [22]. 
The original SPIKE trial was a prospective, randomized, 
open-label, multicenter, blinded end point (PROBE) 
study to evaluate the efficacy of sitagliptin in preventing 
the progression of atherosclerosis in patients with T2DM 
and the primary outcome was the change in carotid IMT 
during the 2-year intervention period. The study design, 
study schedule, and outcomes of the original SPIKE trial 
have been described in detail previously [22].
Subjects
Participants eligible for the SPIKE trial were patients 
with T2DM in whom the target of blood glucose control 
specified in the Treatment Guide for Diabetes (Edited 
by Japan Diabetes Society in 2010) was not achieved 
(HbA1c  ≥  7.0%), despite insulin therapy in addition 
to dietary/exercise therapy or concomitant therapeu-
tic drugs for T2DM other than DPP-4 inhibitors over a 
period of 3 months or longer. Exclusion criteria were (1) 
type 1 diabetes mellitus or secondary diabetes, (2) severe 
infections before or after surgery or severe trauma, (3) 
myocardial infarction, angina pectoris, cerebral stroke, 
or cerebral infarction, (4) retinopathy requiring laser 
photocoagulation and/or vitrectomy, or history of 
these treatments within 1  year, (5) moderate or severe 
renal dysfunction (serum creatinine: male,  ≥  1.4  mg/
dL; female,  ≥  1.2  mg/dL), (6) severe liver dysfunction 
(aspartate aminotransferase  ≥  100  IU/L), (7) moderate 
or severe heart failure (New York Heart Association stage 
III or higher), (8) under treatment with an incretin prepa-
ration, such as other DPP-4 inhibitors, at the start of the 
study, (9) receiving therapeutic drugs not concomitantly 
administrable with incretin preparations with regard to 
the National Health Insurance program, such as DPP-4 
inhibitors, at the start of the study, (10) pregnant, lactat-
ing, or possibly pregnant females or those planning to 
become pregnant, (11) medical history of hypersensitiv-
ity to investigational drugs, or (12) judged as ineligible by 
clinical investigators.
T2DM patients with no past history of apparent CVD 
who periodically attended the Outpatient Diabetes Clin-
ics at 12 centers across Japan were asked to participate 
in this study and all patients who agreed to participate 
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were enrolled. Originally, a total of 282 patients were 
enrolled and randomly allocated into either the sitaglip-
tin treatment group (n = 142) or the conventional treat-
ment group (using drugs other than the DPP-4 inhibitor) 
(n = 140). After excluding 8 patients from analyses (they 
withdrew from the study and/or objected to the inclusion 
of their data in any analysis), 137 subjects in the sitaglip-
tin treatment group and 137 in the conventional treat-
ment group were included in the full analysis set.
The protocols of the original study and this sub-anal-
ysis were approved by the Institutional Review Board 
of each participating institution in compliance with the 
Declaration of Helsinki and current legal regulations in 
Japan. Written informed consent was obtained from all 
the participants after full explanation of the study.
This study has been registered on the University Hospi-
tal Medical Information Network Clinical Trials Registry, 
which is a non-profit organization in Japan and meets the 
requirements of the International Committee of Medical 
Journal Editors (UMIN000007396, UMIN000028664).
Ultrasound examination
B-mode ultrasonography of the carotid artery was per-
formed using an ultrasound machine with a high-fre-
quency (> 7.5-MHz) linear transducer. According to the 
guidelines of the Japan Society of Ultrasonics [27], scan-
ning of the extracranial common carotid artery (CCA), 
the carotid bulb, and the internal carotid artery in the 
neck was performed bilaterally in three different lon-
gitudinal projections as well as transverse projections. 
The IMT was measured as the distance between 2 par-
allel echogenic lines corresponding to the blood-intima 
and media-adventitia interface on the posterior wall of 
the artery. The measurements of mean IMT of the CCA 
(mean-IMT-CCA) were performed using automated 
digital edge-detection software (IntimaScope; MEDIA 
CROSS, Tokyo, Japan) [28]. The software system aver-
aged 200 points of IMT values in the segment 2 cm proxi-
mal to the dilation of the carotid bulb. The measurements 
of maximum IMT of the CCA (max-IMT-CCA) were 
performed at the site of the thickest point in the CCA. 
The method for determining IMT has been described in 
detail in previous reports [22].
The echogenicity of the arterial wall was evaluated 
based on the GSM method in a gray-scale range of 0–255 
(0 as the darkest and 255 as the brightest tone). Adobe 
Photoshop software (Adobe Systems, version 7.0, San 
Jose, CA, USA) was used for image standardization 
and calculation of gray-scale values. In accordance with 
the previous report, the standardization of the B-mode 
image was performed using a curve option, so that the 
GSM for the blood ranged from 0 to 5, and for the adven-
titia from 185 to 195 [29]. Then, the mean-IMT-CCA 
area (the segment 2  cm proximal to the dilation of the 
carotid bulb) was delineated with a freehand tool, and 
the GSM of the selected area was read from the entire 
delineated area. Similarly, if there was an atherosclerotic 
plaque lesion (i.e. focal elevated lesion with max-IMT-
CCA > 1.0 mm), the GSM of the plaque lesion was also 
measured using the same method. In the event multiple 
plaque lesions were found in one individual, the plaque 
with the greatest thickness was subject to GSM measure-
ment and the GSM value was used as the subject’s repre-
sentative value. To avoid inter-reader variability, all scans 
were electronically stored and read in random order by 
a single reader (K. A.) who was unaware of the clinical 
characteristics and the treatment group of the subjects.
Outcome measures
The primary outcome of this study was the change of 
GSM value in the mean-IMT-CCA area (especially, the 
arithmetic average of the right and the left GSM values in 
one individual) during the 104-week observation period. 
In cases where atherosclerotic plaque lesions were found, 
the changes of the GSM value in the plaques were also 
evaluated. The definitions of the GSM measures used in 
this study are as follows:
  • Mean GSM-CCA: the primary outcome of this study. 
The arithmetic average of the right and left GSM-
CCA values. (If either the right or left GSM-CCA 
value was not obtained, the value of the other side 
was used as the mean GSM-CCA value).
  • Right GSM-CCA: the GSM value of the intima-
media complex measured in the mean-IMT-CCA 
area (the segment 2  cm proximal to the dilation of 
the carotid bulb) of the right common carotid artery.
  • Left GSM-CCA: the GSM value of the intima-media 
complex measured in the mean-IMT-CCA area (the 
segment 2 cm proximal to the dilation of the carotid 
bulb) of the left common carotid artery.
  • Right GSM-plaque: the GSM value of the plaque 
lesion (max-IMT-CCA  >  1.0  mm) with the great-
est thickness measured in the right common carotid 
artery.
  • Left GSM-plaque: the GSM value of the plaque lesion 
(max-IMT-CCA  >  1.0  mm) with the greatest thick-
ness measured in the left common carotid artery.
Statistical analyses
All values are reported as mean ±  SD, median (range), 
or actual number of subjects with the percentage in 
parentheses.
The primary end point was the change in GSM of 
the carotid wall from baseline to 104  weeks. The pri-
mary analysis was performed using the mixed-effects 
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model for repeated measures (MMRM) including treat-
ment group, time (week), baseline GSM, and interaction 
between treatment group and time with an unstructured 
covariance structure to model within-subject variability. 
Subgroup analyses were also performed in subgroups by 
baseline sex, age, duration of diabetes, body mass index 
(BMI), HbA1c, presence of hypertension, presence of 
dyslipidemia, use of renin–angiotensin–aldosterone sys-
tem inhibitors, and use of statins. In this subgroup analy-
sis, differences in parameters from baseline to 104 weeks 
between groups were analyzed by the Student’s t-test. 
Baseline and follow-up group comparisons were assessed 
with the Student t test or Wilcoxon rank sum test for 
continuous variables and Fisher’s exact test for categori-
cal variables.
To evaluate the associations between change in the 
mean GSM-CCA and other clinical parameters such as 
age, gender, body mass index (BMI), HbA1c, serum lipid 
levels (e.g. TC, HDL-C, TG), blood pressure, smoking 
status, administration of the anti-diabetic drugs other 
than insulin and DPP-4 inhibitors, anti-hyperlipidemic 
drugs, and anti-hypertensive drugs, and mean-IMT-
CCA, regression analyses including treatment group as a 
covariate were performed.
All statistical tests were two-sided with a 5% signifi-
cance level. Analyses were performed using SAS 9.4 soft-
ware (SAS Institute Inc., Cary, NC).
Results
Baseline characteristics of study subjects
The baseline demographic and clinical characteristics of 
the 274 study participants (137 subjects in the sitaglip-
tin group and 137 in the conventional treatment group) 
have been previously reported [22]. In summary, there 
were no significant differences between the sitagliptin 
group and the conventional treatment group in terms of 
the clinical parameters: the percentage of males was 61 
and 60% (p = 1.00), age was 64 ± 10 and 64 ± 10 years 
(p = 0.90), the percentage of current smoker was 22 and 
21% (p =  0.22), duration of T2DM was 17.2 ±  8.5 and 
17.3  ±  8.7  years (p  =  0.94), HbA1c was 8.1  ±  1.1 and 
8.0 ± 1.0% (p = 0.45), BMI was 25 ± 4 and 25 ± 4 kg/
m2 (p = 0.88), the prevalence of hypertension was 55 and 
63% (p  =  0.22), the prevalence of dyslipidemia was 66 
and 61% (p = 0.45), and the percentage of statin use was 
48 and 46% (p = 0.81), respectively..
Effect of sitagliptin on metabolic factors and carotid IMT
Effect of sitagliptin on metabolic factors and carotid 
IMT have been also previously reported [22]. In sum-
mary, sitagliptin treatment had a more potent glu-
cose-lowering effect than the conventional treatment 
(−  0.5 ±  1.0% vs. −  0.2 ±  0.9%, p =  0.004) without an 
increase in hypoglycemia. However, regarding serum 
lipid profiles, blood pressure, and markers of inflam-
mation and endothelial injury (i.e. hs-CRP, interleu-
kin-6, ICAM-1 and VCAM-1), there were no significant 
between-group differences in changes from baseline to 
104 weeks (data not shown). Reductions in the mean and 
left maximum IMT, but not right maximum IMT, of the 
common carotid arteries at 104 weeks were significantly 
greater after sitagliptin treatment than after conventional 
treatment (−  0.029  mm [SE 0.013] vs. 0.024  mm [SE 
0.013], p = 0.005; − 0.065 mm [SE 0.027] vs. 0.022 mm 
[SE 0.026], p  =  0.021, and −  0.007  mm [SE 0.031] vs. 
0.027 mm [SE 0.031], p = 0.45, respectively) [22].
Effect of sitagliptin on the ultrasonic tissue characteristics 
of the carotid wall
At baseline, plaque lesions were observed in the right 
CCA in 139 subjects (74 subjects in the sitagliptin group 
and 65 in the conventional treatment group) and in the 
left CCA in 157 subjects (80 subjects in the sitaglip-
tin group and 77 in the conventional treatment group), 
respectively. The GSM values of these plaques were 
measured. There were no significant differences in all the 
GSM measures (i.e. mean GSM-CCA, right GSM-CCA, 
left GSM-CCA, right GSM-Plaque, and left GSM-Plaque) 
between the two treatment groups at baseline (Table 1).
The magnitude of the change in GSM values dur-
ing the treatment period was evaluated using the 
MMRM (Table  1). The mean GSM-CCA significantly 
increased in the sitagliptin treatment group (adjusted 
ΔGSM =  2.40 ±  1.19 [mean ±  SE], p =  0.044) but not 
in the in the conventional treatment group (adjusted 
ΔGSM  =  1.32  ±  1.19, p  =  0.27). In the sitaglip-
tin treatment group, right GSM-Plaque (adjusted 
ΔGSM =  5.49 ±  2.69, p =  0.044) and left GSM-Plaque 
(adjusted ΔGSM  =  5.10  ±  2.50, p  =  0.044) also sig-
nificantly increased during the 104-week observation 
period. Similarly, right GSM-CCA and left GSM-CCA 
tended to increase during the 104-week observation 
period, while it did not reach the statistical significance 
(adjusted ΔGSM = 2.39 ± 1.38, p = 0.084 and adjusted 
ΔGSM = 2.08 ± 1.48, p = 0.16, respectively). However, 
in the conventional treatment group, there were no sig-
nificant changes in all the GSM measures (i.e. mean 
GSM-CCA, right GSM-CCA, left GSM-CCA, right 
GSM-Plaque, and left GSM-Plaque) during the 104-week 
observation period.
Similar findings were shown even after adjustment for 
possible confounding factors such as age, gender, BMI, 
HbA1c, serum lipid levels, blood pressure, smoking sta-
tus, and administration of anti-diabetic, anti-hyperten-
sive, anti-hyperlipidemic and anti-platelet drugs (data 
not shown).
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However, there was no significant difference in the 
change in GSM measures from baseline at 52 and 
104 weeks between the two groups.
Differences in Δchange in mean GSM-CCA in 
patients treated with or without sitagliptin in sub-
groups were shown as Fig.  1. This subgroup analysis 
revealed similar results, while there was a significant 
between-treatment-group difference in Δchange in mean 
GSM-CCA in patients with dyslipidemia.
Regression analyses revealed that there was no statisti-
cally significant association between change in the mean 
GSM-CCA and clinical parameters such as age, gender, 
BMI, HbA1c, serum lipid levels (e.g. TC, HDL-C, TG), 
blood pressure, smoking status, and administration of the 
Table 1 The effect of sitagliptin on the GSM of the carotid wall
The primary outcome of this study was the change of Mean GSM-CCA (sown in italics). Data are mean ± SD unless otherwise stated
Comparisons of GSMs during treatment with those at baseline were performed with one-sample t-test based on a mixed-effects model for repeated measures. 
Differences in Δchange in GSM from baseline at 52 and 104 weeks between groups were analyzed with a mixed-effects model for repeated measures. Treatment 
group, week, interactions between treatment group and week, and baseline GSM were included as fixed effects
CI confidence interval, GSM gray-scale median, CCA common carotid artery, SE standard error
* p < 0.05
n Sitagliptin treatment group n Conventional treatment group Adj. mean difference (95% CI) p value between-group
Mean GSM‑CCA (weeks)
 Baseline 137 50.6 ± 18.6 136 52.6 ± 18.3 0.36
 52 130 51.1 ± 17.9 126 52.0 ± 17.6 0.66
 104 120 52.6 ± 16.9 122 53.5 ± 20.3 0.69
Mean change (SE) (weeks)
 52 0.65 (1.11) 0.25 (1.14) 0.40 (− 2.74, 3.53) 0.80
 104 2.40 (1.19)* 1.32 (1.19) 1.08 (− 2.23, 4.39) 0.52
Right GSM‑CCA (weeks)
Baseline 136 51.3 ± 20.6 136 52.8 ± 18.9 0.53
 52 129 51.2 ± 19.1 126 53.1 ± 18.8 0.41
 104 120 53.2 ± 18.2 122 53.4 ± 20.6 0.94
Mean change (SE) (weeks)
 52 0.14 (1.30) 1.26 (1.32) − 1.13 (− 4.77, 2.53) 0.54
 104 2.39 (1.38) 0.85 (1.37) 1.53 (− 2.30, 5.36) 0.43
Left GSM‑CCA (weeks)
 Baseline 136 49.9 ± 19.9 136 52.5 ± 21.2 0.30
 52 130 50.9 ± 19.4 126 50.9 ± 19.5 0.99
 104 120 51.9 ± 19.0 122 53.6 ± 22.2 0.52
Mean change (SE) (weeks)
 52 1.12 (1.38) − 0.46 (1.40) 1.58 (− 2.29, 5.45) 0.42
 104 2.08 (1.48) 2.12 (1.48) − 0.04 (− 4.17, 4.09) 0.98
Right GSM‑plaque (weeks)
 Baseline 74 51.4 ± 19.5 65 55.8 ± 21.5 0.21
 52 72 51.7 ± 19.3 56 55.6 ± 22.9 0.30
 104 61 53.5 ± 20.4 62 59.2 ± 23.6 0.16
Mean change (SE) (weeks)
 52 2.06 (2.04) 2.80 (2.23) − 0.74 (− 6.77, 5.28) 0.81
 104 5.49 (2.69)* 4.20 (2.71) 1.29 (− 6.30, 8.88) 0.74
Left GSM‑plaque (weeks)
 Baseline 80 52.6 ± 23.5 77 55.4 ± 20.9 0.43
 52 76 51.2 ± 19.4 69 54.5 ± 20.5 0.32
 104 73 54.5 ± 21.3 73 51.9 ± 17.5 0.42
Mean change (SE) (weeks)
 52 1.15 (2.19) − 0.05 (2.24) 1.20 (− 5.01, 7.41) 0.70
 104 5.10 (2.50)* − 0.35 (2.57) 5.45 (− 1.66, 12.56) 0.13
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anti-diabetic drugs other than insulin and DPP-4 inhibi-
tors, anti-hyperlipidemic drugs, and anti-hypertensive 
drugs, and mean-IMT-CCA.
Discussion
Many previous studies have provided the evidences that 
incretin-related agents such as GLP-1 analogues and 
DPP-4 inhibitors provide beneficial effects against ath-
erosclerosis [7, 20–22, 30, 31]. Although the PROLOGUE 
trial, a study to evaluate whether DPP-4 inhibitors affect 
atherosclerosis, did not show an additional effect of sit-
agliptin on the progression of carotid IMT [32], sev-
eral studies demonstrated that DPP-4 inhibitors more 
potently inhibited the progression of carotid IMT than 
conventional treatment in patients with T2DM [21, 22, 
30]. However, it remains unclear whether these agents 
affect the tissue characteristics of the carotid arterial wall.
The present study, a post hoc sub-analysis using data 
obtained from the SPIKE study showed that sitaglip-
tin treatment significantly increased the GSM value, an 
index of ultrasonic tissue characteristics, of the carotid 
arterial wall over a 104-week observation period, while 
conventional treatment did not affect the GSM value. 
This finding was complementary with the result of the 
original SPIKE study showing that sitagliptin treatment 
more potently inhibited the progression of carotid IMT 
than conventional treatment in patients with T2DM [22]. 
Our study was also consistent with another previous 
study using samples from asymptomatic patients under-
going carotid endarterectomy that revealed that incretin 
therapy–treated plaques presented with higher collagen 
content and less inflammation and oxidative stress than 
non-incretin–treated plaques, indicating a more stable 
plaque phenotype [33].
Fig. 1 Differences in Δchange in mean GSM‑CCA patients treated with or without sitagliptin in subgroup analysis. Differences in Δchange in mean 
GSM‑CCA from baseline at 104 weeks in patients treated with or without sitagliptin were analyzed by the Student’s t‑test. Subgroup analyses were 
performed in subgroups by baseline sex, age, duration of diabetes, BMI, HbA1c, presence of hypertension, presence of dyslipidemia, use of renin–
angiotensin–aldosterone system inhibitors, and use of statins. Data are expressed as mean with 95% confidence interval. CI confidence interval, BMI 
body mass index, RAS inhibitors of renin–angiotensin–aldosterone system
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The precise mechanism how sitagliptin improved the 
tissue characteristic of the carotid arterial wall remains 
unclear. Hypercholesterolemia, oxidative stress, inflam-
mation, and insulin resistance are major risk factors for 
the formation of the vulnerable plaque [34, 35]. How-
ever, in the present study, neither serum lipid profiles nor 
inflammation markers were significantly associated with 
change in the mean GSM-CCA. Improvement in hyper-
glycemia may be related to the improvement of the tissue 
characteristics of the carotid arterial wall, since reduc-
tion in HbA1c was tended to be larger in the sitagliptin 
treatment group [22]. Low plasma adiponectin levels 
are associated with increased plaque vulnerability [36]. 
Interestingly, atherosclerotic plaques of T2DM patients 
showed lower levels of adiponectin and adaptor protein 
PH domain and leucine zipper containing 1 (APPL1), an 
adaptor protein that interact directly with adiponectin 
receptors, compared with non-diabetic patients. It was 
also shown that current incretin-users presented higher 
adiponectin and APPL1 content compared with never 
incretin users [37]. These findings suggest a potential 
role of adiponectin/APPL1 signaling mediating the ben-
eficial effect of sitagliptin on the tissue characteristic of 
the carotid arterial wall. In addition, recent studies sug-
gest that DPP-4 may play a direct role in vascular inflam-
mation and atherosclerosis independent of its metabolic 
actions [11, 38–40]. Thus, direct anti-atherosclerotic 
effect of sitagliptin on vascular cells is another possi-
ble explanation for its beneficial effect on carotid arte-
rial wall, since DPP-4 inhibitors had anti-atherosclerotic 
effects in both a GLP-1-dependent and GLP-1-independ-
ent manners [8–13].
Several limitations of our study should be discussed. 
First, although a significant increase in GSM value dur-
ing the treatment period was observed in sitagliptin 
treatment group alone, there was no between-group dif-
ference in the changes of GSM values between the two 
treatment groups. Therefore, it would be premature to 
conclude that sitagliptin treatment significantly improved 
the tissue characteristics of the carotid arterial wall. Sec-
ond, the present study is a post hoc sub-analysis using 
data obtained from the SPIKE study. Third, the ultra-
sound settings for each image were not always standard-
ized. However, the blood was used as the reference for 
black and the adventitia as the reference for white, and 
gain settings for measurements within an individual 
were similar throughout the study. Therefore, the impact 
of gain of ultrasound beam on the GSM value would be 
quite small, if any. Fourth, compared with the SPIKE trial 
showing beneficial effect of sitagliptin on progression 
of carotid IMT, in the PROLOGUE trial the change in 
carotid IMT in the sitagliptin group did not differ signifi-
cantly from that in the conventional treatment group [22, 
32]. As Oyama, et al. described in their paper, one possi-
ble explanation for this discrepancy is that higher preva-
lence of statin use in the PROLOGUE study as compared 
to the SPIKE trial masked the beneficial effect of sitag-
liptin, since statins potently suppress IMT progression. 
In addition, in the PROLOGUE study, additional use of 
both pioglitazone and biguanides increased in the con-
ventional treatment group, possibly contributing to the 
suppression of IMT progression. Thus, administration 
of anti-diabetic, anti-hyperlipidemic, and anti-hyperten-
sive drugs may affect the plaque components as well as 
its thickness. Although the baseline medical prescrip-
tions were almost matched in this post hoc analysis of 
the SPIKE trial, it was not possible to adjust for the effect 
of changes in therapeutic regimen during the observa-
tion period. Another possible explanation for the differ-
ent effect of sitagliptin on progression of carotid IMT 
between these two studies is that the baseline charac-
teristics of the participants, such as severity of T2DM, 
HbA1c level, and the prevalence of hypertension, dys-
lipidemia, and cardiovascular disease, differed between 
them. Therefore, it would thus be premature to general-
ize our findings to the T2DM patients with higher risk for 
atherosclerosis.
Conclusions
In conclusion, a post hoc sub-analysis suggests that the 
tissue characteristics of the carotid arterial wall were 
improved in the sitagliptin treatment group during the 
104-week treatment period but not in the conventional 
treatment group. However, the statistically significant 
additional effect of sitagliptin on carotid GSM relative to 
conventional treatment was not demonstrated. Prespeci-
fied studies with large sample size would be necessary to 
confirm our findings.
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